4-(Piperidin-4-yl)indolin-2-one → 3-[3-Methyl-5-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-ylmethylene]-4-piperidin-4-yl-1,3-dihydroindol-2-one
반응식
[NH:1]1[CH2:6][CH2:5][CH:4]([C:7]2[CH:15]=[CH:14][CH:13]=[C:12]3[C:8]=2[CH2:9][C:10](=[O:16])[NH:11]3)[CH2:3][CH2:2]1.[CH3:17][C:18]1[CH:22]=[C:21]([C:23]([N:25]2[CH2:30][CH2:29][N:28]([CH3:31])[CH2:27][CH2:26]2)=[O:24])[NH:20][C:19]=1[CH:32]=O>>[CH3:17][C:18]1[CH:22]=[C:21]([C:23]([N:25]2[CH2:26][CH2:27][N:28]([CH3:31])[CH2:29][CH2:30]2)=[O:24])[NH:20][C:19]=1[CH:32]=[C:9]1[C:8]2[C:12](=[CH:13][CH:14]=[CH:15][C:7]=2[CH:4]2[CH2:3][CH2:2][NH:1][CH2:6][CH2:5]2)[NH:11][C:10]1=[O:16]참가 물질
3
실험 절차
4-Piperidin-4-yl-1,3-dihydro-indol-2-one (45 mg, 0.2 mmol) was condensed with 3-methyl-5-(4-methylpiperazine-1-carbonyl)-1H-pyrrole-2-carbaldehyde (52 mg, 0.23 mmol) to give the title compound.
출처 및 근거
- ORD 기록
- ord-0af659d525b94311ad971c20b903a897
- 출처 데이터셋
- uspto-grants-2006_05